Top Page
Aprea Therapeutics
(NASDAQ:APRE)
Aprea Therapeutics (APRE) vs. SPDR S&P 500 ETF (SPY)
Aprea Therapeutics Business Overview & Revenue Model
Aprea Therapeutics Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 285.76K | 1.50M | 583.23K | 0.00 | 0.00 |
| Gross Profit | 264.04K | -7.86M | 576.18K | -16.40M | -271.68K |
| EBITDA | -13.23M | -14.30M | -14.28M | -37.37M | -36.86M |
| Net Income | -12.60M | -12.96M | -14.29M | -112.66M | -36.54M |
Balance Sheet | |||||
| Total Assets | 15.93M | 23.98M | 22.65M | 30.16M | 56.82M |
| Cash, Cash Equivalents and Short-Term Investments | 14.60M | 22.85M | 21.61M | 28.79M | 53.08M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 190.47K |
| Total Liabilities | 3.49M | 4.67M | 4.39M | 4.51M | 7.32M |
| Stockholders Equity | 13.17M | 19.31M | 18.26M | 25.64M | 49.51M |
Cash Flow | |||||
| Free Cash Flow | -12.89M | -13.57M | -12.27M | -25.01M | -37.69M |
| Operating Cash Flow | -12.89M | -13.56M | -12.18M | -25.01M | -37.69M |
| Investing Cash Flow | 0.00 | -15.48K | -93.09K | 0.00 | 0.00 |
| Financing Cash Flow | 4.64M | 14.82M | 5.14M | 682.97K | 1.75M |
Aprea Therapeutics Technical Analysis
Aprea Therapeutics Risk Analysis
Aprea Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $20.99M | -0.94 | -74.15% | ― | 6.29% | 7.42% | |
48 Neutral | $19.69M | -0.53 | -189.72% | ― | ― | 70.57% | |
47 Neutral | $8.73M | -0.67 | -87.05% | ― | -62.75% | 23.87% | |
44 Neutral | $4.67M | -0.27 | -334.42% | ― | ― | -228.89% | |
44 Neutral | $6.87M | -11.35 | -253.43% | ― | ― | 94.52% |
Aprea Therapeutics Corporate Events
On March 16, 2026, Aprea reported fourth-quarter and full-year 2025 results and highlighted early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 trial, where two PPP2R1A-mutated endometrial cancer patients achieved unconfirmed partial responses by February 2026 and five additional patients showed stable disease, with a favorable safety profile observed during dose escalation. The company set the Phase 2 dose for ATRN-119, then paused further monotherapy enrollment to pursue combination strategies, completed two private placements raising about $8.7 million, appointed Eugene Kennedy as Chief Medical Advisor, and ended 2025 with $14.6 million in cash and a reduced quarterly operating loss, stating that existing funds and January 2026 proceeds should support operations into the first quarter of 2027.
The most recent analyst rating on (APRE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
On February 18, 2026, Aprea Therapeutics reported additional preliminary data from its ongoing first-in-human Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051 in advanced solid tumors, highlighted by a second unconfirmed partial response in a patient with advanced endometrial cancer at the 220 mg dose. The patient, whose tumor carries a PPP2R1A mutation, showed 50% tumor shrinkage and an 87% drop in CA-125 with only Grade 1 adverse events, contributing to a dataset that now includes two unconfirmed partial responses, five cases of stable disease, and generally favorable tolerability, supporting the drug’s potential in genomically defined, difficult-to-treat cancers and guiding further enrollment in PPP2R1A-mutated endometrial and HPV-positive head and neck cancer cohorts.
The ACESOT-1051 study has treated 22 patients across doses from 10 mg to 220 mg, with unconfirmed partial responses seen at 150 mg and 220 mg in endometrial cancers harboring PPP2R1A mutations and stable disease observed in multiple tumor types including colon, uterine and head and neck cancers. These emerging signals of anti-tumor activity without class-limiting toxicity bolster Aprea’s strategy to differentiate APR-1051 through an improved therapeutic index and underpin planned trial expansion and further data updates expected later in 2026.
The most recent analyst rating on (APRE) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
On January 28, 2026, Aprea Therapeutics entered into a securities purchase agreement with new and existing healthcare-focused institutional investors and company insiders for a $5.6 million private placement of 6,288,857 shares of common stock (or pre-funded warrants) and accompanying common stock purchase warrants, priced at the Nasdaq “at-the-market” minimum price of $0.89 per unit, with warrants exercisable at $0.765 per share for two years. The financing, expected to close on or about January 30, 2026, is structured with standard ownership caps, no price-reset or anti-dilution ratchets beyond customary adjustments, and registration rights for resale, and is accompanied by amended restrictions on future equity issuance; Aprea plans to use the net proceeds for general corporate purposes and research and development, including adding patients to key dose levels in its ongoing Phase 1 ACESOT-1051 study of APR-1051, where on January 29, 2026 it also reported a first unconfirmed partial response, a development that could support more robust dose optimization data and potentially strengthen the program’s value and clinical trajectory.
The most recent analyst rating on (APRE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
On January 9, 2026, Aprea Therapeutics updated its corporate presentation, outlining a development roadmap through 2026 that highlights multiple DDR-focused drug candidates and clinical milestones in early-stage oncology trials. The company detailed progress on its ATR inhibitor ATRN-119, for which further monotherapy enrollment has been paused in favor of exploring combination strategies, and on its WEE1 inhibitor APR-1051, which is being advanced toward clinical proof-of-concept as a potentially safer alternative in a target class historically limited by toxicity. The refreshed deck emphasizes Aprea’s strategy to capitalize on synthetic lethality as a validated cancer-killing approach, positioning the firm to benefit from rising global cancer incidence and sustained demand for targeted therapies, while showcasing an experienced management team and board with deep expertise in oncology drug development and commercialization.
The most recent analyst rating on (APRE) stock is a Hold with a $0.89 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.